Pioglitazone
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Pioglitazone and local guidelines before prescribing.
Thiazolidinedione
Mechanism
Thiazolidinedione PPAR-gamma agonist improving insulin sensitivity.
Uses
Type 2 diabetes.
Dosing
- Pioglitazone Type 2 | 15–30 mg daily (max 45 mg). Contraindicated in heart failure; fluid retention, fractures, bladder cancer caution.
Endocrinology: Diabetes
Side effects
Fluid retention, weight gain, fractures, heart failure, bladder cancer risk.
Interactions
Gemfibrozil raises levels; insulin increases oedema.
Contraindications and cautions
Heart failure, bladder cancer, hepatic impairment
Monitoring
Weight, LFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Contraindicated in hepatic impairment
Overdose and reversal
Supportive
Special advice
Contraindicated in heart failure; stop if macular oedema or haematuria without cause.
More from the textbook: uses, cautions and other points
- Drugs — calcium channel blockers (amlodipine), NSAIDs, steroids, pioglitazone.
Cardiology: Presentations - Pioglitazone: Can cause fluid retention and aggravate heart failure.
Cardiology: Heart Failure › 2.34 🚫 Medications That Can Worsen Heart Failure - Pioglitazone | Insulin sensitiser; avoid in heart failure and bladder cancer; fractures, weight gain.
Endocrine: Anatomy Physiology and Pharmacology - Pioglitazone - avoid in heart failure and bladder cancer.
Endocrine: Anatomy Physiology and Pharmacology - Heart failure: Continue SGLT2 inhibitors for heart and kidney benefit. Avoid pioglitazone .
Endocrinology: Diabetes - Further glucose lowering: Options are a GLP-1 agonist or tirzepatide (preferred where recommended), a DPP-4 inhibitor, pioglitazone (not in heart failure), a sulfonylurea (if eGFR is above 30), or insulin. Do not combine a GLP-1 agonist or tirzepatide with a DPP-4 inhibitor (same pathway).
Endocrinology: Diabetes
Where it is discussed in the book
- Cardiology: Presentations (1 mention)
- Cardiology: Heart Failure (1 mention)
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Diabetes (5 mentions)
- Gastroenterology: Liver disease (1 mention)
- Oncology: Urology and Genital cancers (1 mention)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (1 mention)
- Clinical pharmacology and prescribing: Prescribing in special groups (1 mention)
- Integrated cardiology chapter (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)